33994-36-4Relevant academic research and scientific papers
Synthesis of poly(sulfonate ester)s by ADMET polymerization
Parkhurst, Rebecca R.,Balog, Sandor,Weder, Christoph,Simon, Yoan C.
, p. 53967 - 53974 (2014)
Many hydrocarbon polymers containing heteroatom defects in the main chain have been investigated as degradable polyethylene-like materials,including aliphatic polyesters.Here, acyclic diene metathesis (ADMET) polymerization was used for the synthesis of aliphatic poly(sulfonate ester)s.The requisite sulfonate ester containing-diene monomers with varying numbers of methylene groups was synthesized, and their polymerization in the presence of ruthenium-N-heterocyclic (Ru-NHC) alkylidene catalysts was studied. A clear negative neighboring group effect (NNGE) was observed for shorter dienes, either inhibiting polymerization or resulting in low-molecular-weight oligomers. The effect was absent when undec-10-en-1-yl undec-10-ene-1-sulfonate was employed as the monomer, and its ADMET polymerization afforded polymers with appreciable number-average molecular weights of up to 37000 g mol-1 and a dispersity of 1.8.These polymers were hydrogenated to afford the desired polyethylene-like systems.The thermal and morphological properties of both saturated and unsaturated polymers were investigated.The incorporation of sulfonate ester groups in the polymer backbone offers an interesting alternative to other heteroatoms and helps further the understanding of the effects of these defects on the overall polymer properties.
HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS
-
Page/Page column 360; 361, (2018/03/25)
The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
-
Paragraph 0404; 0405, (2018/06/12)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
6-MEMBERED URACIL ISOSTERES
-
Paragraph 0493, (2018/06/12)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
-
Paragraph 0509-0510, (2018/06/12)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
-
Paragraph 0502; 0503, (2018/06/12)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
URACIL CONTAINING COMPOUNDS
-
Paragraph 0468-0469, (2018/07/31)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
-
Paragraph 0408-0409, (2017/01/26)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
-
Paragraph 0420; 0421, (2017/01/26)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE
-
Paragraph 0378; 0379, (2017/02/09)
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
